The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Bebtelovimab Information for the Public
Bebtelovimab is a treatment for mild-to-moderate COVID-19 in patients 12 years of age and older who are at high risk for progression to severe COVID-19, including hospitalization or death, when other COVID-19 medications are not accessible.
Bebtelovimab Fact Sheet for Patients, Parents and Caregivers
Frequently Asked Questions About Bebtelovimab
On February 11, 2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the medication Bebtelovimab. Bebtelovimab is an IV injection used for treating mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg (88 lbs) and who are at high risk for severe COVID-19, including hospitalization or death.
A health care provider will determine whether Bebtelovimab is an appropriate treatment for COVID-19.
How does Bebtelovimab work?
Bebtelovimab blocks the virus from entering your cells and makes it easier for your immune system to find and kill the virus.
How do I know if I am a candidate for Bebtelovimab?
Work with your health care provider to determine if you are a candidate for Bebtelovimab. You should consider this treatment if you are immunocompromised, not up to date on your COVID-19 vaccine, or have one of the following conditions:
- Older age (for example ≥65 years of age)
- Obesity or being overweight (e.g., BMI >25 kg/m2), or BMI ≥85th percentile pediatrics
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (e.g., COPD, moderate to severe asthma, etc.)
- Sickle cell disease
- Neurodevelopmental disorders (e.g., cerebral palsy) or other complexity conditions
- Medical-related technological dependence (e.g., tracheostomy, gastrostomy)
Is there anything I need to tell my health care provider before Bebtelovimab is prescribed?
Please let your health care provider know if you:
- Have allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products)
How is Bebtelovimab given?
- Bebtelovimab is given if you have tested positive for COVID-19, and you have had symptoms for seven days or less. (The date symptoms started, or tested positive is day zero)
- Bebtelovimab will be given as an injection through a vein (intravenously or IV) over at least 30 seconds. You will be observed by your health care provider for at least one hour after you receive bebtelovimab.
How much will Bebtelovimab cost?
Currently, both commercially and federally provided Bebtelovimab are available. Health care providers should bill insurance for commercially purchased Bebtelovimab and preserve the federally provided Bebtelovimab to people who are under and uninsured.
Where can I receive Bebtelovimab?
Bebtelovimab is available at many locations in Michigan. Find a bebtelovimab administration site.
What if my health care provider doesn’t prescribe me any of the COVID-19 therapeutics available?
Your health care provider might not be aware of the treatment options available for you. Direct your health care provider to the provider’s page of the MDHHS therapeutics website at Michigan.gov/COVIDTherapy.
Test to Treat sites are another option to access these important medications. At Test to Treat sites, you can get tested for COVID-19, and a qualified health care provider will determine if COVID-19 medications are right for you. If you are eligible for treatments, you can receive your prescribed medication at the Test to Treat site, or at a nearby pharmacy. Find a Test to Treat site.
Further information for patients and caregivers can be found at:Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Bebtelovimab for Coronavirus Disease 2019(COVID-19)
For a list of conditions for persons at risk for COVID-19 disease severity visit conditions identified by the CDC.